
---
title: '什么情况？业绩爆发股价却大跌，CXO小龙头公布财报，葛兰两大基金坚守！一批高增长股砸出深坑'
categories: 
 - 金融
 - 证券时报网
 - 数据
headimg: 'https://data.stcn.com/djsj/202208/W020220820657108171413.png'
author: 证券时报网
comments: false
date: Sat, 20 Aug 2022 18:12:00 GMT
thumbnail: 'https://data.stcn.com/djsj/202208/W020220820657108171413.png'
---

<div>   
<p>超跌绩优股后市能否跑赢大盘？</p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300363" code="300363">博腾股份</a>8月19日晚间发布半年度报告，公告显示，公司实现营业收入39.14亿元，同比增长211.67%；归母净利润12.12亿元，同比增长465.01%；扣非归母净利润12.11亿元，同比增长501.87%。报告显示，2022年上半年，得益于核心业务板块原料药CDMO业务的强劲增长，公司创下史上最好的半年度业绩。</p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300363" code="300363">博腾股份</a>业绩符合预期，此前公司预告上半年归母净利润11.91亿元至12.12亿元，昨日披露的半年报净利润已触及预测上限。公开信息显示，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300363" code="300363">博腾股份</a>是一家按照国际标准为跨国制药公司和生物技术公司提供医药定制研发生产服务的国家级高新技术企业。</p><p>作为CXO小龙头，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300363" code="300363">博腾股份</a>也是机构扎堆重仓股。最新半年报显示，知名基金经理葛兰旗下两大基金，中欧医疗健康A和中欧医疗创新A，继续坚守该股，期末市值逾20亿元。此外，广发医疗保健A、全国社保基金420组合等机构现身公司前十大。截至最新收盘，公司总市值超过330亿元。</p><p>曾几何时，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300363" code="300363">博腾股份</a>是超级大牛股之一，一度从7元下方涨至100元上方，最大涨幅接近15倍。今年该股股价出现了下跌趋势，累计跌幅超过30%。</p><p style="text-align:center"><img class="rich_pages wxw-img" data-ratio="0.6583333" src="https://data.stcn.com/djsj/202208/W020220820657108171413.png" data-type="png" data-w="1080" data-imgqrcoded="1" style="margin: 0px; padding: 0px; max-width: 100%; height: auto !important; overflow-wrap: break-word !important; vertical-align: middle; width: 562px; box-sizing: border-box;" oldsrc="W020220820657108171413.png" referrerpolicy="no-referrer"></p><p><strong>一批高增长股砸出深坑</strong></p><p>还有一批中报高增长股今年股价出现下跌情形。证券时报·数据宝统计，5家以上机构评级且中报净利润增长超过50%的个股中，有25股年内股价跌超15%。中报净利润增幅最高的是<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688575" code="688575">亚辉龙</a>，增长超6倍。此外，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300363" code="300363">博腾股份</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000408" code="000408">藏格矿业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600499" code="600499">科达制造</a>等个股中报增长超4倍。</p><p>从行业看，电子行业中业绩暴跌、股价大跌的公司最多，达到9只。其次是医药生物行业，有6股。分析人士表示，对于电子行业以及医药生物行业，市场预期部分细分行业或许已经到了景气周期顶部，这导致部分上市公司不受市场青睐。</p><p>从机构关注度来看，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002624" code="002624">完美世界</a>和<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603259" code="603259">药明康德</a>两股均有38家机构评级。近期<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002736" code="002736">国信证券</a>、财信证券等众多券商发布了<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002624" code="002624">完美世界</a>的研报。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002736" code="002736">国信证券</a>认为公司老游戏基本盘稳固，新游戏增量显著，经过阵痛期，公司游戏主业逐渐步入稳健上升通道，维持“买入”评级。</p><p>此外，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603659" code="603659">璞泰来</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300363" code="300363">博腾股份</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS605358" code="605358">立昂微</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603456" code="603456">九洲药业</a>等个股均有20多家机构评级。</p><p style="text-align:center"><img class="rich_pages wxw-img" data-ratio="0.4324074" src="https://data.stcn.com/djsj/202208/W020220820657109277287.png" data-type="png" data-w="1080" data-imgqrcoded="1" style="margin: 0px; padding: 0px; max-width: 100%; height: auto !important; overflow-wrap: break-word !important; vertical-align: middle; width: 562px; box-sizing: border-box;" oldsrc="W020220820657109277287.png" referrerpolicy="no-referrer"></p><p><strong>北上资金增持9股</strong></p><p>从北上资金动向来看，部分绩优超跌股近期获资金大幅加仓。</p><p>数据宝统计，8月以来按照成交均价计算，北上资金增持9股，5股获增持超亿元，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603259" code="603259">药明康德</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603659" code="603659">璞泰来</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002850" code="002850">科达利</a>等个股获北上资金增持均超3亿元。</p><p>从股价表现来看，芯片板块股表现较好。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688536" code="688536">思瑞浦</a>和<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688521" code="688521">芯原股份</a>-U8月以来累计涨幅均超过20%。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603456" code="603456">九洲药业</a>和<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300775" code="300775">三角防务</a>同期则均跌超10%。新能源汽车产业链表现平淡。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002850" code="002850">科达利</a>、科大制造、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603659" code="603659">璞泰来</a>等个股同期跌幅均超5%。</p><p>渤海证券指出，短期来看，一方面经济数据承压下，对稳增长的信心重建需要过程；另一方面，中报业绩压力对市场形成考验，因此短期还需耐心等待机会的到来。行业配置方面，高景气领域将相对占优；与此同时，8月15日政策利率的超预期调降带来分母端的边际改善，市场风险偏好获得抬升，成长板块相对占优；因而配置层面，一方面可关注高景气板块的扩散机会，另一方面可关注成长板块中拥挤度相对不高的半导体、电子、通信等。（数据宝 陈见南）</p><p style="text-align:center"><img class="rich_pages wxw-img" data-cropselx1="0" data-cropselx2="562" data-cropsely1="0" data-cropsely2="905" data-ratio="1.5682926829268293" src="https://data.stcn.com/djsj/202208/W020220820657112649340.png" data-type="png" data-w="820" data-imgqrcoded="1" style="margin: 0px; padding: 0px; max-width: 100%; height: 905px; overflow-wrap: break-word !important; vertical-align: middle; width: 577px; box-sizing: border-box;" oldsrc="W020220820657112649340.png" referrerpolicy="no-referrer"></p><p>声明：数据宝所有资讯内容不构成投资建议，股市有风险，投资需谨慎。</p>
  
</div>
            